1
|
Czepielewski RS, Jaeger N, Marques PE, Antunes MM, Rigo MM, Alvarenga DM, Pereira RV, da Silva RD, Lopes TG, da Silva VD, Porto BN, Menezes GB, Bonorino C. GRPR antagonist protects from drug-induced liver injury by impairing neutrophil chemotaxis and motility. Eur J Immunol 2017; 47:646-657. [DOI: 10.1002/eji.201646394] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 01/03/2017] [Accepted: 03/08/2017] [Indexed: 01/29/2023]
Affiliation(s)
- Rafael S. Czepielewski
- Laboratório de Imunologia Celular e Molecular; Instituto de Pesquisas Biomédicas (IPB); Porto Alegre RS Brazil
| | - Natália Jaeger
- Laboratório de Imunologia Celular e Molecular; Instituto de Pesquisas Biomédicas (IPB); Porto Alegre RS Brazil
| | - Pedro E. Marques
- Departamento de Bioquímica e Imunologia; Laboratório de Imunofarmacologia, UFMG; Belo Horizonte MG Brazil
| | - Maísa M. Antunes
- Center for Gastrointestinal Biology, Departamento de Morfologia; Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais; MG Brazil
| | - Maurício M. Rigo
- Laboratório de Imunologia Celular e Molecular; Instituto de Pesquisas Biomédicas (IPB); Porto Alegre RS Brazil
| | - Débora M. Alvarenga
- Center for Gastrointestinal Biology, Departamento de Morfologia; Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais; MG Brazil
| | - Rafaela V. Pereira
- Center for Gastrointestinal Biology, Departamento de Morfologia; Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais; MG Brazil
| | - Rodrigo D. da Silva
- Laboratório de Imunologia Celular e Molecular; Instituto de Pesquisas Biomédicas (IPB); Porto Alegre RS Brazil
| | - Tiago G. Lopes
- Laboratório de Anatomia Patológica do Hospital São Lucas da PUCRS; Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS); Porto Alegre RS Brazil
| | - Vinícius D. da Silva
- Laboratório de Anatomia Patológica do Hospital São Lucas da PUCRS; Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS); Porto Alegre RS Brazil
| | - Bárbara N. Porto
- Laboratório de Imunologia Clínica e Experimental; Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS); Porto Alegre RS Brazil
| | - Gustavo B. Menezes
- Center for Gastrointestinal Biology, Departamento de Morfologia; Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais; MG Brazil
| | - Cristina Bonorino
- Laboratório de Imunologia Celular e Molecular; Instituto de Pesquisas Biomédicas (IPB); Porto Alegre RS Brazil
- Department of Surgery, School of Medicine; University of California at San Diego; La Jolla California
| |
Collapse
|
2
|
Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011; 152:4610-9. [PMID: 21971158 DOI: 10.1210/en.2011-1485] [Citation(s) in RCA: 116] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Glucagon-like peptide-1(7-36NH2) (GLP-1) is secreted by the intestinal L cell in response to both nutrient and neural stimulation, resulting in enhanced glucose-dependent insulin secretion. GLP-1 is therefore an attractive therapeutic for the treatment of type 2 diabetes. The antidiabetic drug, metformin, is known to increase circulating GLP-1 levels, although its mechanism of action is unknown. Direct effects of metformin (5-2000 μm) or another AMP kinase activator, aminoimidazole carboxamide ribonucleotide (100-1000 μm) on GLP-1 secretion were assessed in murine human NCI-H716, and rat FRIC L cells. Neither agent stimulated GLP-1 secretion in any model, despite increasing AMP kinase phosphorylation (P < 0.05-0.01). Treatment of rats with metformin (300 mg/kg, per os) or aminoimidazole carboxamide ribonucleotide (250 mg/kg, sc) increased plasma total GLP-1 over 2 h, reaching 37 ± 9 and 29 ± 9 pg/ml (P < 0.001), respectively, compared with basal (7 ± 1 pg/ml). Plasma activity of the GLP-1-degrading enzyme, dipeptidylpeptidase-IV, was not affected by metformin treatment. Pretreatment with the nonspecific muscarinic antagonist, atropine (1 mg/kg, iv), decreased metformin-induced GLP-1 secretion by 55 ± 11% (P < 0.05). Pretreatment with the muscarinic (M) 3 receptor antagonist, 1-1-dimethyl-4-diphenylacetoxypiperidinium iodide (500 μg/kg, iv), also decreased the GLP-1 area under curve, by 48 ± 8% (P < 0.05), whereas the antagonists pirenzepine (M1) and gallamine (M2) had no effect. Furthermore, chronic bilateral subdiaphragmatic vagotomy decreased basal secretion compared with sham-operated animals (7 ± 1 vs. 13 ± 1 pg/ml, P < 0.001) but did not alter the GLP-1 response to metformin. In contrast, pretreatment with the gastrin-releasing peptide antagonist, RC-3095 (100 μg/kg, sc), reduced the GLP-1 response to metformin, by 55 ± 6% (P < 0.01) at 30 min. These studies elucidate the mechanism underlying metformin-induced GLP-1 secretion and highlight the benefits of using metformin with dipeptidylpeptidase-IV inhibitors in patients with type 2 diabetes.
Collapse
Affiliation(s)
- Andrew J Mulherin
- Department of Physiology, University of Toronto, 1 King's College Circle, Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
3
|
Inan S, Dun NJ, Cowan A. Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice. Peptides 2011; 32:286-92. [PMID: 21126550 PMCID: PMC3995915 DOI: 10.1016/j.peptides.2010.11.022] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Revised: 11/11/2010] [Accepted: 11/12/2010] [Indexed: 11/16/2022]
Abstract
Gastrin-releasing peptide (GRP) has been implicated in the itch-scratch cycle. We investigated if this gut-brain-skin peptide plays a role in the compulsive, hindleg scratching of the neck of mice by 5'-guanidinonaltrindole (GNTI), the kappa opioid receptor antagonist, and in the antipruritic activity of nalfurafine, the kappa opioid agonist. Previously, we showed that GNTI (0.03-1mg/kg, s.c.) elicits dose-related scratching and that nalfurafine (0.001-0.02mg/kg, s.c.) inhibits this behavior in mice. Utilizing immunohistochemistry, GRP positive nerve fibers were detected in mouse skin and superficial layer of the dorsal horn of the spinal cord as well as GRP positive cells in the dorsal root ganglion. Pretreating mice with either a pseudopeptide GRP receptor antagonist, RC-3095 (10-30mg/kg, s.c. at -15min), or a peptide GRP receptor antagonist, [d-Phe(6)]bombesin(6-13) methyl ester (2-100nmol, i.t. at -10min), did not suppress GNTI-induced scratching. However, pretreating mice with either antagonist inhibited scratching precipitated by the GRP receptor agonist, GRP(18-27) (2nmol, i.t.). Pretreating mice with a muscarinic M(1) receptor agonist, McN-A-343 (1.5-15μg/5μl, i.t. at -10min) antagonized GNTI-induced scratching. Norbinaltorphimine (20mg/kg, i.p. at -18 to -20h), a kappa opioid antagonist, countered the antiscratch activity of nalfurafine. We conclude that (a) the GRP receptor system does not mediate GNTI-induced scratching and (b) the kappa opioid system is involved, at least in part, in the scratch suppressing activity of nalfurafine.
Collapse
Affiliation(s)
- Saadet Inan
- Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Nae J Dun
- Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | - Alan Cowan
- Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA
- Corresponding author: Alan Cowan, PhD, Department of Pharmacology, Temple University School of Medicine, 3420 N Broad Street, Philadelphia, PA 19140, Telephone: (215)-707-4110, Fax: (215)-707-7068,
| |
Collapse
|
4
|
Presti-Torres J, de Lima MN, Scalco FS, Caldana F, Garcia VA, Guimarães MR, Schwartsmann G, Roesler R, Schröder N. Impairments of social behavior and memory after neonatal gastrin-releasing peptide receptor blockade in rats: Implications for an animal model of neurodevelopmental disorders. Neuropharmacology 2007; 52:724-32. [PMID: 17097693 DOI: 10.1016/j.neuropharm.2006.09.020] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2006] [Revised: 09/04/2006] [Accepted: 09/22/2006] [Indexed: 01/30/2023]
Abstract
The gastrin-releasing peptide receptor (GRPR) has been implicated in central nervous system (CNS) diseases, including neurodevelopmental disorders associated with autism. In the present study we examined the effects of GRPR blockade during the neonatal period on behavioral measures relevant to animal models of neurodevelopmental disorders. Male Wistar rats were given an intraperitoneal (i.p.) injection of either saline (SAL) or the GRPR antagonist [D-Tpi(6), Leu(13) psi(CH(2)NH)-Leu(14)] bombesin (6-14) (RC-3095; 1 or 10mg/kg) twice daily for 10days from postnatal days (PN) 1 to 10. Animals treated with RC-3095 showed pronounced deficits in social interaction when tested at PN 30-35 and impaired 24-h retention of memory for both novel object recognition (NOR) and inhibitory avoidance (IA) tasks tested at PN 60-71. Neither short-term memory tested 1.5h posttraining nor open field behavior were affected by neonatal GRPR blockade. The implications of the findings for animal models of neurodevelopmental disorders are discussed.
Collapse
Affiliation(s)
- J Presti-Torres
- Neurobiology and Developmental Biology Laboratory and Graduate Program in Cellular and Molecular Biology, Faculty of Biosciences, Pontifical Catholic University, 90619-900 Porto Alegre, RS, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, Richter M, Souza F, da Rocha AB, Souza FH, Pohlmann P, De Nucci G. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24:403-12. [PMID: 16505950 DOI: 10.1007/s10637-006-6886-5] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Bombesin/gastrin-releasing peptides (BN/GRP) were shown to bind selectively to cell surface receptors, stimulating the growth of various types of malignancies in murine and human models. The novel BN/GRP synthetic receptor antagonist, RC-3095, was able to produce long-lasting tumor regressions in murine and human tumor models in vitro and in vivo. Animal toxicology studies showed no detectable organ toxicity apart from local irritation at the injection site. The purpose of this study was to determine the safety and feasibility of the administration of RC-3095 by daily subcutaneous injections in patients with advanced and refractory solid malignancies. Twenty-five patients received RC-3095 once or twice-daily at doses ranging from 8 to 96 ug/kg. Dose was escalated in groups of 3-5 patients per dose level. The only toxicity observed was local discomfort in the injection site at the highest doses. A single dose administration of RC-3095 at the highest dose level (96 ug/kg) was tested in a clearly hypergastrinemic individual with the Zollingen-Ellison syndrome and produced a decrease in plasma gastrin down to 50% of basal levels in 6 h. There was no objective tumor responses in patients included in the study. A short-lasting minor tumor response was observed in a patient with a GRP-expressing progressive medullary carcinoma of the thyroid. Due to problems with the analytical method, plasma pharmacokinetic data was obtained only from two patients included at the highest dose level. In these patients, RC-3095 reached plasma concentrations >100 ng/mL for about 8 h, which were within therapeutic levels on the basis of prior data obtained in mice and rats. The plasma elimination half-life was between 8.6-10.9 h. Due to the occurrence of local toxicity at the injection site, the dose escalation procedure could not be fully evaluated up to a maximum tolerated dose. Thus, a recommended dose of RC-3095 for Phase II trials could not be clearly established. Considering the novelty of its mechanism of action and impressive preclinical anti-tumor activity, further studies exploiting new formulations of RC-3095 for human use, such as slow-release preparations, and analogues with a more favorable pharmacokinetics are warranted.
Collapse
Affiliation(s)
- G Schwartsmann
- South-American Office for Anticancer Drug Development (SOAD), Porto Alegre, Brazil.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ehrlich K, Plate S, Stroff T, Gretzer B, Respondek M, Peskar BM. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: role of cyclooxygenase-2. THE AMERICAN JOURNAL OF PHYSIOLOGY 1998; 274:G955-64. [PMID: 9612278 DOI: 10.1152/ajpgi.1998.274.5.g955] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study investigates the neural pathways, mediators, and cyclooxygenase isoenzymes involved in the gastroprotection conferred by peptone in rats. Intragastric perfusion with 8% peptone protected against gross and histological damage induced by subsequent perfusion with 50% ethanol. The gastroprotective effect of peptone was near maximally inhibited by gastrin immunoneutralization, inactivation of capsaicin-sensitive afferent neurons, calcitonin gene-related peptide (CGRP) immunoneutralization, blockade of gastrin receptors, CGRP, bombesin/gastrin-releasing peptide (GRP), or somatostatin receptors, and by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine methyl ester and was partially (46%) counteracted by atropine. Indomethacin and the selective cyclooxygenase-2 inhibitors NS-398 and L-745,337 dose dependently (50% inhibitory dose, 4.2, 0.8, and 1.5 mg/kg, respectively) attenuated the peptone-induced protection. Dexamethasone was ineffective. These results indicate that protective effects of peptone involve endogenous gastrin and possibly somatostatin and are mediated by capsaicin-sensitive afferent, cholinergic, and bombesin/GRP neurons. CGRP, NO, and prostaglandins participate as essential mediators. The study provides evidence that prostaglandins derived from a constitutive cyclooxygenase-2 contribute to mucosal defense in the presence of ulcerogens and thus participate in homeostatic functions of the stomach.
Collapse
Affiliation(s)
- K Ehrlich
- Department of Experimental Clinical Medicine, Ruhr-University of Bochum, Germany
| | | | | | | | | | | |
Collapse
|
7
|
Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc Natl Acad Sci U S A 1997; 94:10913-8. [PMID: 9380734 PMCID: PMC23529 DOI: 10.1073/pnas.94.20.10913] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Epidermal growth factor (EGF) and its receptors (EGFR) play important roles in tumorigenesis. In various experimental cancers, treatment with antagonists of bombesin/gastrin-releasing peptide (BN/GRP) produces a reduction in EGFRs, concomitant to inhibition of tumor growth. To investigate the mechanisms involved, we monitored concentrations of BN/GRP antagonist RC-3095 in serum of mice, rats, and hamsters given a single subcutaneous or intravenous injection of this analog. In parallel studies, we measured levels and mRNA expression of EGFRs in estrogen-dependent and independent MXT mouse mammary cancers, following a single subcutaneous administration of RC-3095 to tumor-bearing mice. Peak values of RC-3095 in serum were detected 2 min after intravenous or 15 min after subcutaneous injection. The levels of RC-3095 declined rapidly and became undetectable after 3-5 hr. In the estrogen-dependent MXT tumors, the concentration of EGF receptors was reduced by about 60% 6 hr following injection and returned to original level after 24 hr. Levels of mRNA for EGFR fell parallel with the receptor number and were nearly normal after 24 hr. In the hormone-independent MXT cancers, the number of EGFRs decreased progressively, becoming undetectable 6 hr after injection of RC-3095, and returned to normal values at 24 hr, but EGFR mRNA levels remained lower for 48 hr. Thus, in spite of rapid elimination from serum, BN/GRP antagonist RC-3095 can induce a prolonged decrease in levels and mRNA expression of EGFRs. These findings may explain how single daily injections of BN/GRP antagonists can maintain tumor growth inhibition.
Collapse
Affiliation(s)
- K Szepeshazi
- Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA 70146, USA
| | | | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- R de Castiglione
- Farmitalia Carlo Erba (now Pharmacia), Research Centre, Nerviano (MI), Italy
| | | |
Collapse
|
9
|
Lach E, Coy DH, Dumont P, Landry Y, Gies JP. Gastrin releasing peptide-preferring bombesin binding sites in human lung. Eur J Pharmacol 1994; 265:117-20. [PMID: 7883024 DOI: 10.1016/0014-2999(94)90233-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Characterization of bombesin binding sites in healthy human lung was performed through direct binding techniques. There was limited binding in the absence of trypsin and chymotrypsin inhibitors, suggesting important activities of both enzymes in human lung and/or increased sensitivity of the bombesin sites toward them. In human lung membranes, bombesin, gastrin releasing peptide (GRP) and GRP-preferring bombesin receptor antagonists displaced [125I-Tyr4]bombesin binding with high affinities (36-177 nM), whereas neuromedin B possessed a lower affinity of 2878 nM. [D-F5Phe6,D-Ala11]bombesin-(6-13)-methyl ester, the most active GRP-preferring bombesin antagonist as yet reported, had the highest affinity among all antagonists tested whereas neuromedin B had the lowest affinity. These data demonstrate that the bombesin binding sites in the human lung are of the GRP-preferring type.
Collapse
Affiliation(s)
- E Lach
- Laboratoire de Neuroimmunopharmacologie Pulmonaire, INSERM CJF 9105, Université Louis Pasteur-Strasbourg I, Faculté de Pharmacie, Illkirch, France
| | | | | | | | | |
Collapse
|
10
|
Varga G, Adrian TE, Coy DH, Reidelberger RD. Bombesin receptor subtype mediation of gastroenteropancreatic hormone secretion in rats. Peptides 1994; 15:713-8. [PMID: 7937351 DOI: 10.1016/0196-9781(94)90101-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Bombesin is a potent releaser of many gut and pancreatic hormones including gastrin, glucose-dependent insulinotropic polypeptide (GIP), pancreatic polypeptide (PP), cholecystokinin (CCK), enteroglucagon, and insulin. Three mammalian bombesin-like peptides, gastrin-releasing peptide (GRP), neuromedin C (NMC or GRP-10), and neuromedin B (NMB), and two bombesin receptor subtypes, GRP preferring and NMB preferring, have been characterized. We used a highly potent, selective antagonist of the GRP-preferring receptor, [D-Phe6]bombesine(6-13)-methylester ([D-Phe6]Bn(6-13)OMe), to determine the receptor subtype mediating bombesin-induced secretion of gastrin, GIP, PP, peptide YY (PYY), and insulin, as well as the importance of endogenous bombesin-like peptides in controlling basal secretion of these hormones. Unanesthetized rats received femoral vein infusion of saline, bombesin (10 nmol/kg/h), [D-Phe6]Bn(6-13)OMe (1000 nmol/kg/h), or bombesin plus [D-Phe6]Bn(6-13)OMe. Blood was withdrawn from jugular vein catheters before and 30 min after the start of infusions. Plasma gastrin, GIP, PP, PYY, and insulin were measured by specific radioimmunoassays. [D-Phe6]Bn(6-13)OMe alone reduced basal insulin levels by 28% (p < 0.05) but did not alter basal levels of plasma PP, GIP, PYY, or gastrin (p > 0.05 for each). Bombesin infusion significantly increased plasma levels of each hormone (p < 0.0001 for each). [D-Phe6]Bn(6-13)OMe completely blocked bombesin-induced increases in PP, insulin, and gastrin, and almost completely blocked increases in GIP and PYY (p < 0.01 for each). Our results suggest that (a) exogenous bombesin significantly stimulates PP, insulin, GIP, PYY, and gastrin secretion, (b) bombesin-induced secretion of these hormones is primarily mediated by the GRP-preferring receptor, and (c) an endogenous bombesin-like peptide acting at this receptor subtype plays an important physiological role in control of basal secretion of insulin but not PP, GIP, PYY, or gastrin.
Collapse
Affiliation(s)
- G Varga
- Institute of Experimental Medicine, Budapest, Hungary
| | | | | | | |
Collapse
|